Chardan lowered the firm’s price target on Forte Biosciences (FBRX) to $61 from $64 and keeps a Buy rating on the shares. The firm updates its model after the company’s FY24 update and expectations of Celiac Disease data expected in Q2.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX: